Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells  Jeffrey A. Brockman, Rajnish A. Gupta, Raymond.

Slides:



Advertisements
Similar presentations
Volume 131, Issue 1, Pages (July 2006)
Advertisements

Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma  Ya-Wei Qiang, Bart.
IL-18 Downregulates Collagen Production in Human Dermal Fibroblasts via the ERK Pathway  Hee Jung Kim, Seok Bean Song, Jung Min Choi, Kyung Moon Kim,
Volume 118, Issue 3, Pages (March 2000)
The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.
Volume 6, Issue 5, Pages (November 2004)
Inhibition of hypoxia-induced cyclooxygenase-2 by Korean Red Ginseng is dependent on peroxisome proliferator-activated receptor gamma  Heewon Song, Young.
Volume 145, Issue 2, Pages (August 2013)
Volume 127, Issue 2, Pages (August 2004)
Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells by Weiqing.
Volume 120, Issue 7, Pages (June 2001)
Volume 132, Issue 5, Pages (May 2007)
Volume 126, Issue 1, Pages (January 2004)
Volume 128, Issue 1, Pages (January 2005)
Volume 6, Issue 3, Pages (September 2004)
PTF1α/p48 and cell proliferation
Volume 134, Issue 7, Pages (June 2008)
Volume 118, Issue 4, Pages (April 2000)
Prolyl Hydroxylase-3 Is Down-regulated in Colorectal Cancer Cells and Inhibits IKKβ Independent of Hydroxylase Activity  Jing Xue, Xuebing Li, Shi Jiao,
The homeodomain protein Cdx2 regulates lactase gene promoter activity during enterocyte differentiation  Rixun Fang, Nilda A. Santiago, Lynne C. Olds,
by Guang Yang, Shu-Ching Huang, Jane Y. Wu, and Edward J. Benz
Volume 134, Issue 1, Pages (January 2008)
Volume 126, Issue 1, Pages (January 2004)
Volume 60, Issue 5, Pages (November 2001)
Human osteoarthritic chondrocytes are impaired in matrix metalloproteinase-13 inhibition by IFN-γ due to reduced IFN-γ receptor levels  R. Ahmad, M. El.
Suppression of fibroblast growth factor receptor signaling inhibits pancreatic cancer growth in vitro and in vivo  Markus Wagner, Martha E. Lopez, Mitch.
Volume 123, Issue 3, Pages (September 2002)
Volume 26, Issue 1, Pages (January 2007)
The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.
Oncogenic ras induces gastrin gene expression in colon cancer
J. F Schaefer, M. S. , M. L Millham, M. A. , B de Crombrugghe, M. D
Volume 115, Issue 4, Pages (October 1998)
Volume 17, Issue 3, Pages (February 2005)
Volume 114, Issue 6, Pages (June 1998)
Volume 123, Issue 1, Pages (July 2002)
Volume 133, Issue 4, Pages (October 2007)
HDAC Activity Is Required for p65/RelA-Dependent Repression of PPARδ-Mediated Transactivation in Human Keratinocytes  Lene Aarenstrup, Esben Noerregaard.
MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α
Mechanisms of cross hyporesponsiveness to toll-like receptor bacterial ligands in intestinal epithelial cells  Jan-Michel Otte, Elke Cario, Daniel K.
Role of p38 MAPK in Transforming Growth Factor β Stimulation of Collagen Production by Scleroderma and Healthy Dermal Fibroblasts  Madoka Sato, Daniel.
Volume 116, Issue 6, Pages (June 1999)
Volume 120, Issue 7, Pages (June 2001)
Volume 64, Issue 1, Pages (July 2003)
Xiaolong Wei, Hai Xu, Donald Kufe  Cancer Cell 
Ginsenoside F1 Protects Human HaCaT Keratinocytes from Ultraviolet-B-Induced Apoptosis by Maintaining Constant Levels of Bcl-2  Enn Hee Lee, Si Young.
MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α
HDAC5, a Key Component in Temporal Regulation of p53-Mediated Transactivation in Response to Genotoxic Stress  Nirmalya Sen, Rajni Kumari, Manika Indrajit.
Volume 16, Issue 24, Pages (December 2006)
Volume 12, Issue 5, Pages (November 2005)
Volume 127, Issue 4, Pages (October 2004)
The p73 Gene Is an Anti-Tumoral Target of the RARβ/γ-Selective Retinoid Tazarotene  Marina Papoutsaki, Mauro Lanza, Barbara Marinari, Steven Nisticò, Francesca.
PPARδ Is a Type 1 IFN Target Gene and Inhibits Apoptosis in T Cells
Volume 20, Issue 4, Pages (November 2005)
IL-18 Downregulates Collagen Production in Human Dermal Fibroblasts via the ERK Pathway  Hee Jung Kim, Seok Bean Song, Jung Min Choi, Kyung Moon Kim,
Volume 119, Issue 1, Pages (July 2000)
Constitutive and regulated secretion of secretory leukocyte proteinase inhibitor by human intestinal epithelial cells  Mustapha Si-Tahar, Didier Merlin,
Volume 122, Issue 2, Pages (February 2002)
Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: implications for long-term graft patency  Sushil.
IL-12 affects Dermatophagoides farinae–induced IL-4 production by T cells from pediatric patients with mite-sensitive asthma  Takeshi Noma, MD, PhD, Izumi.
Leila Khamzina, Philip A Gruppuso, Jack R Wands  Gastroenterology 
Volume 67, Issue 4, Pages (April 2005)
Volume 128, Issue 7, Pages (June 2005)
Volume 57, Issue 2, Pages (October 2000)
Volume 119, Issue 5, Pages (November 2000)
Volume 5, Issue 6, Pages (December 2013)
STAT5a/PPARγ Pathway Regulates Involucrin Expression in Keratinocyte Differentiation  Xiuju Dai, Koji Sayama, Yuji Shirakata, Yasushi Hanakawa, Kenshi.
Volume 31, Issue 6, Pages (December 2009)
Volume 16, Issue 5, Pages (May 2009)
Volume 122, Issue 3, Pages (August 2005)
Pirh2 represses p73-dependent transactivation.
Presentation transcript:

Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells  Jeffrey A. Brockman, Rajnish A. Gupta, Raymond N. DuBois  Gastroenterology  Volume 115, Issue 5, Pages 1049-1055 (November 1998) DOI: 10.1016/S0016-5085(98)70072-1 Copyright © 1998 American Gastroenterological Association Terms and Conditions

Fig. 1 PPARγ is expressed and functionally active in colon cancer cells. (A) PPARγ is expressed at the mRNA level in colon cancer cells. Total RNA (10 μg) from either HCA-7, HCT-15, HCT-116, or Caco-2 cells was subjected to an RT reaction either with (+) or without (−) reverse transcriptase. A 2-μL aliquot from each reaction was subjected to 40 cycles of PCR. Amplification products were resolved in a 2% agarose gel. The identity of the amplicon was confirmed by restriction mapping and DNA sequence analysis. (B) PPARγ protein is present in colon cancer cells. Whole-cell extracts (500 μg) were immunoprecipitated with a PPARγ peptide–specific affinity-purified antibody (1 μg) for 4 hours. Immunoprecipitates were eluted with 50 μL PPARγ peptide (200 μg/mL) overnight. Eluted proteins were resolved on a 10% SDS-PAGE gel, transferred to a polyvinylidene difluoride membrane, and immunoblotted with the same antibody. (C) Cells were transiently transfected with 1 μg PPRE3-tk-luciferase and 0.01 μg pRL-SV40 by lipid transfection. Transfections were treated with 10 μmol/L BRL 49653 (■) or DMSO (control; □) for 12 hours. Cells were harvested and a dual-luciferase assay was performed as described in the Materials and Methods. The means of normalized relative light units from 3 independent transfections are shown. Error bars = SEM. Gastroenterology 1998 115, 1049-1055DOI: (10.1016/S0016-5085(98)70072-1) Copyright © 1998 American Gastroenterological Association Terms and Conditions

Fig. 2 The PPARγ selective agonist BRL 49653 inhibits anchorage-independent growth of cells that overexpress functional PPARγ. (A) Inhibition of anchorage-independent growth by BRL 49653. HCT-15 or HCT-15-G25 cells (3 × 104) were plated into media containing 0.4% (wt/vol) agar, supplemented with either DMSO (control; □) or 10 μmol/L BRL 49653 (■). After 7 days of growth, the number of colonies was determined. The values shown are the means of 3 independent experiments performed in triplicate. Error bars = SEM. (B) BRL 49653 is a selective PPARγ agonist in HCT-15 cells. HCT-15 cells were transiently transfected with expression vectors encoding either PPARα, β, or γ (1.5 μg), PPRE3-tk-luciferase (1 μg), and pRL-SV40 (0.01 μg) by lipid transfection. Transfected cells were treated with 10 μmol/L BRL 49653 (■) or DMSO (control; □) for 12 hours and harvested, and a dual-luciferase assay was performed as described in Materials and Methods. Gastroenterology 1998 115, 1049-1055DOI: (10.1016/S0016-5085(98)70072-1) Copyright © 1998 American Gastroenterological Association Terms and Conditions

Fig. 2 The PPARγ selective agonist BRL 49653 inhibits anchorage-independent growth of cells that overexpress functional PPARγ. (A) Inhibition of anchorage-independent growth by BRL 49653. HCT-15 or HCT-15-G25 cells (3 × 104) were plated into media containing 0.4% (wt/vol) agar, supplemented with either DMSO (control; □) or 10 μmol/L BRL 49653 (■). After 7 days of growth, the number of colonies was determined. The values shown are the means of 3 independent experiments performed in triplicate. Error bars = SEM. (B) BRL 49653 is a selective PPARγ agonist in HCT-15 cells. HCT-15 cells were transiently transfected with expression vectors encoding either PPARα, β, or γ (1.5 μg), PPRE3-tk-luciferase (1 μg), and pRL-SV40 (0.01 μg) by lipid transfection. Transfected cells were treated with 10 μmol/L BRL 49653 (■) or DMSO (control; □) for 12 hours and harvested, and a dual-luciferase assay was performed as described in Materials and Methods. Gastroenterology 1998 115, 1049-1055DOI: (10.1016/S0016-5085(98)70072-1) Copyright © 1998 American Gastroenterological Association Terms and Conditions

Fig. 3 BRL 49653 inhibits cell growth of colon cancer cells. (A) Cells (1 × 105/well) were grown in the continuous presence of either 0, 1, 10, or 25 μmol/L BRL 49653 with equal amounts of DMSO. After 5 days of growth, the number of cells per well was determined. The values shown represent the means of 3 independent wells normalized to the DMSO control, set at 100%. Error bars = SEM. The experiment was performed twice with similar results. (B) Cells were transiently transfected with 1 μg PPRE3-tk-luciferase, and 0.01 μg pRL-SV40 by lipid transfection. Transfected cells were treated with either 0, 1, 10, or 25 μmol/L BRL 49653 for 12 hours and harvested, and a dual-luciferase assay was performed as described in Materials and Methods. ■ HCA-7, HCT-116, ● HCT-15, ▴ HCT-15-G25. Gastroenterology 1998 115, 1049-1055DOI: (10.1016/S0016-5085(98)70072-1) Copyright © 1998 American Gastroenterological Association Terms and Conditions

Fig. 3 BRL 49653 inhibits cell growth of colon cancer cells. (A) Cells (1 × 105/well) were grown in the continuous presence of either 0, 1, 10, or 25 μmol/L BRL 49653 with equal amounts of DMSO. After 5 days of growth, the number of cells per well was determined. The values shown represent the means of 3 independent wells normalized to the DMSO control, set at 100%. Error bars = SEM. The experiment was performed twice with similar results. (B) Cells were transiently transfected with 1 μg PPRE3-tk-luciferase, and 0.01 μg pRL-SV40 by lipid transfection. Transfected cells were treated with either 0, 1, 10, or 25 μmol/L BRL 49653 for 12 hours and harvested, and a dual-luciferase assay was performed as described in Materials and Methods. ■ HCA-7, HCT-116, ● HCT-15, ▴ HCT-15-G25. Gastroenterology 1998 115, 1049-1055DOI: (10.1016/S0016-5085(98)70072-1) Copyright © 1998 American Gastroenterological Association Terms and Conditions

Fig. 4 PPARγ activation induces G1 cell cycle arrest. Either HCT-15 or HCT-15-G25 cells (0.25 × 106) were plated into 6-well plates and allowed to grow to 30% confluence. Cells were then treated with either DMSO or BRL 49653 (10 μmol/L) for 5 days in serum-free media. Cells were harvested, stained with propidium iodide, and analyzed for DNA content by fluorescence-activated cell sorter analysis. The values represent the number of cells in the G1 phase of the cell cycle as a percentage of total cells. Gastroenterology 1998 115, 1049-1055DOI: (10.1016/S0016-5085(98)70072-1) Copyright © 1998 American Gastroenterological Association Terms and Conditions